BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Status:
Recruiting
Trial end date:
2023-11-04
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study of an investigational drug, BIO-11006, for the treatment of lung
metastases in pediatric patients with advanced osteosarcoma or Ewing's sarcoma. This study
will enroll up to 10 patients aged between 5 and 21 at Nicklaus Children's Hospital in Miami,
FL. Patients will receive BIO-11006 in addition to chemotherapy consisting of gemcitabine and
docetaxel. This study will test the hypothesis that BIO-11006 will enhance the effect of the
gemcitabine and docetaxel chemotherapy to treat lung metastases in osteosarcoma and Ewing's
sarcoma.